Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)

Publisher： John Wiley & Sons Inc

E-ISSN： 1096-8652|90|4|327-333

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.4, 2015-04, pp. : 327-333

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Reduced‐dose fludarabine, cyclophosphamide, and rituximab (FCR‐Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 6, 2015-06 ,pp. : 487-492

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Study to Compare the Efficacy and Safety of Obinutuzumab + Venetoclax versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL14)

By  

Oncology Research and Treatment, Vol. 39, Iss. 1-2, 2016-0 ,pp. : 69-71

Karger

Access to resources Recommend Favorite

Ofatumumab‐based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL)

By  

CANCER, Vol. 119, Iss. 21, 2013-11 ,pp. : 3788-3796

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high‐risk relapsed/refractory chronic lymphocytic leukemia patients

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 1, 2015-01 ,pp. : 37-42

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 5, 2015-05 ,pp. : 417-421

John Wiley & Sons Inc

Access to resources Recommend Favorite